TCGA-5L-AAT1-01A-12R-A41B-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 49
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.520
- INTERFERON_ALPHA_RESPONSE+0.470
- INTERFERON_GAMMA_RESPONSE+0.460
- IL6_JAK_STAT3_SIGNALING+0.360
- PANCREAS_BETA_CELLS+0.350
- INFLAMMATORY_RESPONSE+0.300
- COAGULATION+0.290
- COMPLEMENT+0.250
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.230
- KRAS_SIGNALING_UP+0.200
Top 10 suppressed
- E2F_TARGETS-0.650
- G2M_CHECKPOINT-0.600
- MITOTIC_SPINDLE-0.470
- MYC_TARGETS_V2-0.450
- MYC_TARGETS_V1-0.430
- PROTEIN_SECRETION-0.420
- MTORC1_SIGNALING-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.380
- GLYCOLYSIS-0.320
- ESTROGEN_RESPONSE_EARLY-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A0CR-01A-11R-A22K-07 | — | B | 0.896 |
| 2 | TCGA-E9-A5FK-01A-11R-A27Q-07 | — | B | 0.883 |
| 3 | SRR25617853 | — | D | 0.879 |
| 4 | TCGA-44-2661-01A-01R-1107-07 | — | cohortA1 | 0.875 |
| 5 | MNG580 | — | — | 0.875 |
| 6 | TCGA-H7-A76A-01A-51R-A34R-07 | — | — | 0.873 |
| 7 | TCGA-C8-A138-01A-11R-A115-07 | — | A | 0.865 |
| 8 | TCGA-85-A513-01A-12R-A26W-07 | — | cohortA1 | 0.864 |
| 9 | TCGA-CV-A468-01A-11R-A266-07 | — | — | 0.856 |
| 10 | 20030012.LumA | — | A | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.520 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| MYOGENESIS | 0.140 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.140 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.130 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |